Recent limited research conducted in the UK has shown that the weight loss drug 'liraglutide' may be effective in slowing cognitive decline, a significant symptom of Alzheimer's disease. Liraglutide, administered as a daily injection, is also prescribed for diabetes treatment. The results of this limited study, presented at the International Alzheimer's Society conference in the USA, indicate that this drug, also known as 'Saxenda', can slow memory and cognitive decline in Alzheimer's patients. Health authorities predict that the number of individuals suffering from cognitive decline will triple worldwide by 2050, reaching 153 million. Experts state that the significant increase in Alzheimer's patients poses an escalating challenge and threat to the future of public medical services. In this limited study, 204 volunteers participated. Half of them were administered 'liraglutide' produced by Novo Nordisk, while the other half received a placebo. The study did not achieve its ultimate goal of assessing changes in glucose metabolism in the brain or evaluating brain function. However, it did show that the use of this drug reduced the rate of shrinkage in areas of the brain responsible for memory, cognition, language, and decision-making by about 50%. The researchers, conducted under the supervision of experts from Imperial College London, stated that it appears that cognitive decline in those volunteers who took 'liraglutide' for one year decreased by approximately 18%. Experts believe that confirming the findings of this limited study requires more extensive research. Paul Edison, a professor of sciences at Imperial College London and the lead researcher of the new study, stated: 'The slowing of brain shrinkage indicates that liraglutide protects the brain, just as statins protect the heart.' He added: 'Although further research is essential, considering the preliminary evidence, it can be said that liraglutide, in various ways, including reducing brain inflammation, lowering insulin resistance, and decreasing the toxic effects of beta-amyloid and tau, which are hallmark symptoms of Alzheimer's, improves communication between brain cells.'
A Weight Loss Drug May Be Effective in Slowing Alzheimer's Symptoms
A recent UK study suggests that liraglutide, a weight loss drug, may slow cognitive decline in Alzheimer's patients. With the number of Alzheimer's cases expected to triple by 2050, this finding could have significant implications for public health. Further research is needed to confirm these results.
👥 Key Players
📰 What Happened
A recent study in the UK indicated that liraglutide, a weight loss drug, may slow cognitive decline in Alzheimer's patients. The findings suggest that this drug could play a role in managing Alzheimer's symptoms, which is critical given the predicted rise in cases.
- The study involved 204 volunteers, with half receiving liraglutide and half a placebo.
- Results showed a 50% reduction in brain shrinkage rates in those taking liraglutide.
💡 Why It Matters
📚 Background
Alzheimer's disease is a progressive neurological disorder that leads to memory loss and cognitive decline, affecting millions worldwide. Current treatments are limited, making research into new therapies critical.
🏷️ Entities Mentioned
Translated from the original and edited for English readers. View original source →
Translation confidence: 85%